/IDOGEN.ST
IDOGEN.ST Stock - Idogen AB (publ)
Healthcare|BiotechnologySTO
$0.12-2.82%
$0.00 (-2.82%) • Jul 12
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.49
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.13
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IDOGEN.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.12 – $0.12
TARGET (TP)$0.14
STOP LOSS$0.11
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.78
52W High$0.12
52W Low$0.12
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-47,972,000 | $-38,965,000 | $-26,153,000 | $-32,826,480 | $-27,860,627 |
| Net Income | $-47,608,000 | $-38,856,000 | $-26,823,000 | $-32,695,474 | $-27,633,706 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.76 | $-2.02 | $-2.80 | $-5.67 | $-7.34 |
Company Overview
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases. The company was incorporated in 2008 and is headquartered in Lund, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IDOGEN.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.07
Q2 2023
EPS Surprise History
Q3 21
No data
Q4 21
No data
Q1 22
No data
Q2 22
No data
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | May 9, 2023 | — | $-0.07 | — | — |
Q1 2023 | Feb 24, 2023 | — | $-0.18 | — | — |
Q4 2022 | Nov 25, 2022 | — | $-0.20 | — | — |
Q3 2022 | Aug 25, 2022 | — | $-0.15 | — | — |
Q2 2022 | May 4, 2022 | — | $-0.25 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.33 | — | — |
Q4 2021 | Oct 15, 2021 | — | $-0.28 | — | — |
Q3 2021 | Jul 15, 2021 | — | $-0.53 | — | — |
Q2 2021 | Apr 15, 2021 | — | $-0.58 | — | — |
Q1 2021 | Feb 9, 2021 | — | $-0.86 | — | — |
Q4 2020 | Oct 23, 2020 | — | $-0.52 | — | — |
Q3 2020 | Aug 25, 2020 | — | $-0.87 | — | — |
Q2 2020 | May 12, 2020 | — | $-1.27 | — | — |
Q1 2020 | Jan 29, 2020 | — | $-1.51 | — | — |
Q4 2019 | Oct 22, 2019 | — | $-1.22 | — | — |
Q3 2019 | Aug 20, 2019 | — | $-2.06 | — | — |
Q2 2019 | Apr 29, 2019 | — | $-1.23 | — | — |
Q1 2019 | Feb 6, 2019 | — | $-1.91 | — | — |
Q4 2018 | Oct 23, 2018 | — | $-2.06 | — | — |
Q3 2018 | Aug 21, 2018 | — | $-2.11 | — | — |
Latest News
Loading news...
Frequently Asked Questions about IDOGEN.ST
What is IDOGEN.ST's current stock price?
Idogen AB (publ) (IDOGEN.ST) is currently trading at $0.12 per share. The stock has moved -2.82% today.
What is the analyst price target for IDOGEN.ST?
No analyst price targets are currently available for this stock.
What sector is Idogen AB (publ) in?
Idogen AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is IDOGEN.ST's market cap?
Idogen AB (publ) has a market capitalization of $0.01 billion, making it a small-cap company.
Does IDOGEN.ST pay dividends?
No, Idogen AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEGIR.ST
AegirBio AB (publ)
$0.43
Mkt Cap: $0.0B
AMNI.ST
Amniotics AB (publ)
$0.01
Mkt Cap: $0.0B
CYXO.ST
Cyxone AB (publ)
$0.02
Mkt Cap: $0.0B
DIABIO.ST
Diagonal Bio AB (publ)
$0.01
Mkt Cap: $0.0B
L2S.ST
Learning 2 Sleep L2S AB (publ)
$0.02
Mkt Cap: $0.0B
PEXAB.ST
Pexa AB
$0.25
Mkt Cap: $0.0B
PHARM.ST
Pharmiva AB (publ)
$0.56
Mkt Cap: $0.0B
PHLOG-B.ST
Pharmacolog i Uppsala AB (publ)
$0.10
Mkt Cap: $0.0B
VSDB.ST
VibroSense Dynamics AB
$0.75
Mkt Cap: $0.0B
ZICC.ST
Ziccum AB (publ)
$0.25
Mkt Cap: $0.0B
Explore stocks similar to IDOGEN.ST for comparison